Loading...
•
Dec 31, 2023
Adaptive Biotechnologies Q4 2023 Earnings Report
Adaptive Biotechnologies reported financial results for the fourth quarter and full year ended December 31, 2023.
Key Takeaways
Adaptive Biotechnologies reported a revenue of $45.8 million for the fourth quarter of 2023, a 17% decrease compared to the prior year. The MRD business grew by 9%, while the Immune Medicine business decreased by 45%. The net loss for the quarter was $69.5 million, compared to $40.2 million for the same period in 2022.
Revenue for the fourth quarter was $45.8 million, representing a 17% decrease year-over-year.
clonoSEQ test volume increased 49% to 15,680 tests delivered in the fourth quarter of 2023, compared to the fourth quarter 2022.
Operating expenses, including a $25.4 million lease impairment charge, were $116.9 million for the fourth quarter of 2023, a 24% increase year-over-year.
Net loss was $69.5 million for the fourth quarter of 2023, compared to $40.2 million for the same period in 2022.
Revenue by Segment
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...